(Q40385536)

20 September 2017

1 reference

title

Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential (English)

1 reference

20 September 2017

J M Kane

1

1 reference

20 September 2017

1 October 1993

1 reference

20 September 2017

1 reference

20 September 2017

46

1 reference

20 September 2017

4

1 reference

20 September 2017

585-593

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199346040-00002

20 September 2017

0 references

cites work

A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial

1 reference

12 December 2020

Thymosthenic agents, a novel approach in the treatment of schizophrenia

1 reference

12 December 2020

Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients

1 reference

12 December 2020

Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride.

1 reference

12 December 2020

Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

1 reference

12 December 2020

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

12 December 2020

D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics

1 reference

12 December 2020

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

1 reference

12 December 2020

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

1 reference

12 December 2020

Clozapine-related seizures

1 reference

12 December 2020

A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia

1 reference

12 December 2020

Biochemical and behavioural properties of clozapine

1 reference

12 December 2020

Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1

1 reference

12 December 2020

Experiences of long-term treatment with remoxipride: efficacy and tolerability

1 reference

12 December 2020

On the possible mechanisms and predictability of clozapine-induced agranulocytosis

1 reference

12 December 2020

HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia

1 reference

12 December 2020

Clozapine: plasma levels and prolactin response

1 reference

12 December 2020

Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years.

1 reference

12 December 2020

Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia

1 reference

12 December 2020

Biochemical pharmacology of the atypical neuroleptic remoxipride

1 reference

12 December 2020

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

1 reference

12 December 2020

In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone

1 reference

12 December 2020

Clozapine in the treatment of dysphoric mania

1 reference

12 December 2020

Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases.

1 reference

12 December 2020

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

1 reference

12 December 2020

Risperidone: clinical development: north American results

1 reference

12 December 2020

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

1 reference

12 December 2020

A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol

1 reference

12 December 2020

Clozapine: an antipsychotic agent in Parkinson's disease?

1 reference

12 December 2020

Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography

1 reference

12 December 2020

Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia

1 reference

12 December 2020

Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients

1 reference

12 December 2020

Response to clozapine in chronic psychotic patients

1 reference

12 December 2020

Pharmacology of neuroleptics in use in the United States

1 reference

12 December 2020

Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme

1 reference

12 December 2020

The effects of clozapine on tardive dyskinesia

1 reference

12 December 2020

Dimensions of outcome with clozapine

1 reference

12 December 2020

A report of clozapine-induced agranulocytosis in the United States. Incidence and risk factors

1 reference

12 December 2020

Interaction of the atypical neuroleptic clozapine with 5-HT3 receptors in the cerebral cortex and superior cervical ganglion of the rat.

1 reference

12 December 2020

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

12 December 2020

Clozapine for psychosis in Parkinson's disease

1 reference

12 December 2020

The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years

1 reference

12 December 2020

10.2165/00003495-199346040-00002

Identifiers

DOI

1 reference

PubMed ID

7506647

Dimensions Publication ID

20 September 2017

0 references

1 reference

PubMed ID

7506647